Zobrazeno 1 - 6
of 6
pro vyhledávání: '"M L, Ernest"'
Autor:
J P, Dutcher, R I, Fisher, G, Weiss, F, Aronson, K, Margolin, A, Louie, J, Mier, G, Caliendo, J A, Sosman, J R, Eckardt, M L, Ernest, J, Doroshow, M, Atkins
Publikováno v:
The cancer journal from Scientific American. 3(3)
A phase II trial of outpatient subcutaneous (SC) interleukin-2 (rIL-2) plus interferon-alpha (IFN-alpha 2B) was performed in patients with metastatic renal cell cancer. A 5-year follow-up of that Cytokine Working Group study is presented.Forty-seven
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5e38b5c6d578a537e36433c8a03bd790
https://pubmed.ncbi.nlm.nih.gov/9161778
https://pubmed.ncbi.nlm.nih.gov/9161778
Autor:
J A, Sosman, F R, Aronson, M, Sznol, M B, Atkins, J P, Dutcher, G R, Weiss, R E, Isaacs, K A, Margolin, R I, Fisher, M L, Ernest, J, Mier, L, Oleksowicz, J R, Eckhardt, D, Levitt, J H, Doroshow
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 3(1)
Interleukin 6 (IL-6) has antitumor activity comparable to IL-2 in murine models with less toxicity. Because the biological effects of intermittent and continuous infusions may differ, we conducted two concurrent Phase I trials of daily x5, 1-h, and c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::03de004a742327d910c53daea704c567
https://pubmed.ncbi.nlm.nih.gov/9815535
https://pubmed.ncbi.nlm.nih.gov/9815535
Publikováno v:
Cancer. 78(8)
Many patients with advanced transitional cell carcinoma are unable to receive cisplatin-based therapy. The efficacy and toxicity of a carboplatin-based regimen in the treatment of patients with advanced transitional cell carcinoma was therefore evalu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dda8bf7fd32784b5ac579b2997a23559
https://pubmed.ncbi.nlm.nih.gov/8859191
https://pubmed.ncbi.nlm.nih.gov/8859191
Publikováno v:
Cancer. 73(11)
Metastatic renal cell carcinoma (RCC) is largely chemoresistant. The efficacy of cell cycle specific chemotherapeutic agents, particularly those with short half-lives, may be enhanced by the use of constant rate infusion schedules. Infusional floxuri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0bc010044cc74756d78a78cf95cf7f16
https://pubmed.ncbi.nlm.nih.gov/8194022
https://pubmed.ncbi.nlm.nih.gov/8194022
Autor:
Joseph A. Sparano, M Sunderland, R I Fisher, K. Margolin, Geoffrey R. Weiss, M L Ernest, K C Micetich, M Sznol, Janice P. Dutcher, Michael B. Atkins
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 11(10)
PURPOSE To compare the response rate, survival, and toxicity of treatment with high-dose intravenous (IV) bolus interleukin-2 (IL-2) plus interferon alfa-2a (IFN-alpha) with high-dose IL-2 alone in patients with advanced melanoma in a randomized phas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54ae30f047d0230a2f32fc1a5a500712
https://pubmed.ncbi.nlm.nih.gov/8410122
https://pubmed.ncbi.nlm.nih.gov/8410122
Publikováno v:
Cancer. 71(11)
Twenty-nine patients with metastatic renal cell carcinoma (RCC) were treated with constant-infusion floxuridine (FUdR, Roche Laboratories, Nutley, NJ).The initial dosage was 0.075 mg/kg/day for 14 days every 28 days and was increased or decreased by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e9b34e6d01f63d5e7c575def92760064
https://pubmed.ncbi.nlm.nih.gov/8490909
https://pubmed.ncbi.nlm.nih.gov/8490909